STOCK TITAN
  1. Home
  2. Sec-filings
  3. ACRS
  4. [8-K] – Aclaris Therapeutics, Inc. (ACRS) (CIK 0001557746)

[8-K] – Aclaris Therapeutics, Inc. (ACRS) (CIK 0001557746)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock ACRS logo
Aclaris Therapeutics Inc

NASDAQ:ACRS

ACRS Rankings

#4279 Ranked by Market Cap
N/A Ranked by Dividends
#77 Top Loser

ACRS Latest News

Sep 30, 2025
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025
Sep 9, 2025
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
Aug 27, 2025
Aclaris Therapeutics to Participate in Two September Healthcare Conferences
Aug 7, 2025
Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jul 29, 2025
Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

ACRS Latest SEC Filings

Aug 7, 2025
[10-Q] Aclaris Therapeutics, Inc. Quarterly Earnings Report
Aug 7, 2025
[8-K] Aclaris Therapeutics, Inc. Reports Material Event
Aug 5, 2025
[Form 4] Aclaris Therapeutics, Inc. Insider Trading Activity
Aug 5, 2025
[Form 3] Aclaris Therapeutics, Inc. Initial Statement of Beneficial Ownership
Jul 29, 2025
[8-K] Aclaris Therapeutics, Inc. Reports Material Event

ACRS Stock Data

202.58M
105.42M
2.69%
86.19%
5.46%
Biotechnology
Pharmaceutical Preparations
Link
United States
WAYNE